Blueprint Medicines has identified new cAMP-dependent protein kinase catalytic subunit alpha (PRKACA) inhibitors reported to be useful for the treatment of Carney complex (NAME syndrome, LAMB syndrome), McCune-Albright syndrome, polycystic kidney disease and cancer.